Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial

卡培他滨 医学 奥沙利铂 内科学 氟尿嘧啶 危险系数 放化疗 肿瘤科 化疗 胃肠病学 癌症 结直肠癌 置信区间
作者
Ruinuo Jia,Tanyou Shan,Anping Zheng,Yaowen Zhang,Ping Lu,Guifang Zhang,Wang Feng,Zhiqiao Xu,Guobao Zheng,Dongxia Tang,Weiguo Zhang,Wanying Li,Ruonan Li,Yibo Guo,Lina Liu,Xiaoyong Luo,Yingjuan Zheng,Zhiwei Chang,Qiming Wang,Xinshuai Wang,Xiaozhi Yuan,Guoqiang Kong,Shuoguo Li,Yang Ruina,Dan Zhou,Jing Ren,Weijiao Yin,Jingxia Li,Junqian Zhang,Ziqi Wang,Manxi Sheng,Bingyi Xu,Liuyan Li,Xiaoyi Liu,Zhihao Lu,Lixin Wan,Fuyou Zhou,Shegan Gao
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (20): 2436-2445 被引量:4
标识
DOI:10.1200/jco.23.02009
摘要

PURPOSE This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS Patients were randomly assigned to receive two cycles of capecitabine, XELOX, or PF along with concurrent intensity-modulated radiation therapy. Patients in each arm were again randomly assigned to receive two cycles of consolidation chemotherapy or not. The primary end points were 2-year overall survival (OS) rate and incidence of grade ≥3 adverse events (AEs). RESULTS A total of 246 patients were randomly assigned into the capecitabine (n = 80), XELOX (n = 85), and PF (n = 81) arms. In capecitabine, XELOX, and PF arms, the 2-year OS rate was 75%, 66.7%, and 70.9% (capecitabine v PF: hazard ratio [HR], 0.91 [95% CI, 0.61 to 1.35]; nominal P = .637; XELOX v PF: 0.86 [95% CI, 0.58 to 1.27]; P = .444); the median OS was 40.9 (95% CI, 34.4 to 49.9), 41.9 (95% CI, 28.6 to 52.1), and 35.4 (95% CI, 30.4 to 45.4) months. The incidence of grade ≥3 AEs during the entire treatment was 28.8%, 36.5%, and 45.7%, respectively. Comparing the consolidation chemotherapy with the nonconsolidation chemotherapy groups, the median OS was 41.9 (95% CI, 34.6 to 52.8) versus 36.9 (95% CI, 28.5 to 44) months (HR, 0.71 [95% CI, 0.52 to 0.99]; nominal P = .0403). CONCLUSION Capecitabine or XELOX did not significantly improve the 2-year OS rate over PF in DCRT for inoperable locally advanced ESCC. Capecitabine showed a lower incidence of grade ≥3 AEs than PF did.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
义气的海亦完成签到,获得积分20
刚刚
李无敌完成签到,获得积分20
刚刚
大蒜头完成签到,获得积分10
1秒前
1秒前
lalala发布了新的文献求助10
1秒前
2秒前
jason发布了新的文献求助10
2秒前
今后应助初之采纳,获得10
2秒前
Jasper应助shanhai采纳,获得10
3秒前
liyanshang发布了新的文献求助10
3秒前
4秒前
man发布了新的文献求助10
5秒前
感动的秋玲完成签到,获得积分10
5秒前
Gzl发布了新的文献求助50
5秒前
华仔应助义气的海亦采纳,获得10
5秒前
cadnash发布了新的文献求助10
5秒前
Spine Lin发布了新的文献求助10
5秒前
41发布了新的文献求助10
6秒前
zhtgang完成签到,获得积分10
7秒前
阳光的安南完成签到,获得积分10
7秒前
学位论文完成签到,获得积分10
7秒前
Ao发布了新的文献求助10
8秒前
8秒前
脑洞疼应助小春采纳,获得10
8秒前
852应助小柿子采纳,获得10
8秒前
8秒前
研友_Z1WrgL发布了新的文献求助10
9秒前
Jasper应助喜悦寒凝采纳,获得10
10秒前
香蕉觅云应助卜懂得采纳,获得10
10秒前
大林完成签到,获得积分20
10秒前
杜亚完成签到,获得积分10
11秒前
11秒前
Spine Lin完成签到,获得积分10
11秒前
12秒前
13秒前
14秒前
初之发布了新的文献求助10
14秒前
14秒前
14秒前
大林发布了新的文献求助10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970683
求助须知:如何正确求助?哪些是违规求助? 3515337
关于积分的说明 11178055
捐赠科研通 3250580
什么是DOI,文献DOI怎么找? 1795357
邀请新用户注册赠送积分活动 875790
科研通“疑难数据库(出版商)”最低求助积分说明 805166